Cantabio Pharmaceuticals licensed a drug candidate for the treatment of Alzheimer’s disease and dementia from Cambridge Enterprise on Wednesday. The therapy is based on research conducted by led by Cambridge University’s Gergely Tóth and Eckhard Mandelkow at the Max Planck Institute in collaboration with NovAliX and Elan Pharmaceuticals.
Camstent, a UK-based medical materials company commercialising research from Cambridge and Nottingham universities, raised £850,000 ($1.1m) on Wednesday. The money will help the company bring Camstent Foley Catheter, its first product to market, which aims to combat Catheter Acquired Urinary Tract Infections.
Pharmaceutical firm Biohaven has invested an undisclosed amount in series A capital to US-based biotech company Kleo Pharmaceuticals, based on research at the Spiegel Lab at Yale University. The spinout is working on treatments for cancer and infectious diseases. Biohaven itself is also a spinout of Yale, but has also licensed intellectual property of Massachusetts General Hospital, Catalent and ALS Biopharma.
